Literature DB >> 2411169

Influence of intravenous infusions of hydroxyethylstarch (HES) (MW 40,000 and 450,000) on the blood flow properties of healthy volunteers.

A M Ehrly, H Landgraf.   

Abstract

Infusions of hydroxyethylstarch (HES) solutions as plasma substitutes and flow improvers play an increasing role in the treatment of various diseases. Little is known about the effect of HES solutions of different molecular weights on the flow properties of blood i.e. blood viscosity, plasma viscosity, erythrocyte aggregation and erythrocyte deformability (filtrability). In the present study the influence of 500 ml-infusions of a 6% solution of HES (MW 450,000) has been compared to that of 6% solutions of HES 40,000. Infusions of 500 ml of HES 450,000 into healthy persons induced a hemodilution with a subsequent decrease in whole blood viscosity whereas the plasma viscosity increased. Red cell aggregation increased as well, red cell deformability was slightly impaired. Infusions of 500 ml of HES 40,000 into healthy persons were followed by a hemodilution with a decrease in blood and plasma viscosity, a decrease in erythrocyte aggregation and a slight improvement of red cell deformability. The reason for this difference in behaviour and its therapeutical consequences are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411169     DOI: 10.1177/000331978503600107

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

Review 1.  The impact of fluid therapy on microcirculation and tissue oxygenation in hypovolemic patients: a review.

Authors:  Joachim Boldt; Can Ince
Journal:  Intensive Care Med       Date:  2010-05-26       Impact factor: 17.440

2.  Effects of rapid fluid infusion on hemoglobin concentration: a systematic review and meta-analysis.

Authors:  Armin A Quispe-Cornejo; Ana L Alves da Cunha; Hassane Njimi; Wasineenart Mongkolpun; Ana L Valle-Martins; Mónica Arébalo-López; Jacques Creteur; Jean-Louis Vincent
Journal:  Crit Care       Date:  2022-10-23       Impact factor: 19.334

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.